MSC2504877
/ Institute of Cancer Research, EMD Serono
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 19, 2019
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors.
(PubMed, Sci Rep)
- "The combination of MSC2504877 and palbociclib was also effective in suppressing the cellular hyperproliferative phenotype seen in Apc defective intestinal stem cells in vivo. However, the presence of an oncogenic Kras p.G12D mutation in mice reversed the effects of the MSC2504877/palbociclib combination, suggesting one molecular route that could lead to drug resistance."
Clinical • Journal • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1